brentuximab
intetumumab
monospecific
alloantibody
onartuzumab
sotrovimab
indatuximab ravtansine
glembatumumab
sarilumab
immunocarrier
vanucizumab
afutuzumab
dinutuximab
pozelimab
sasanlimab
tigatuzumab
cergutuzumab
zenocutuzumab
heteroclitic
lorvotuzumab
autoepitope
sintilimab
toripalimab
retifanlimab
solitomab
ziltivekimab
amlitelimab
immunopanning
antiustekinumab
antitoxin
robatumumab
siltuximab
idiospecific
pancytokeratin
zanolimumab
immunocharacterize
affitin
caplacizumab
agonistic monoclonal antibody
complement
olendalizumab
hyperimmunized
antigenomic
leronlimab
teneliximab
patritumab
immunoprinting
conatumumab
inotuzumab
duligotuzumab